Hikma Pharmaceuticals Plc Stock Return On Equity

HKMPY Stock  USD 47.48  1.22  2.51%   
Hikma Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Hikma Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Hikma Pink Sheet. The fundamental analysis module provides a way to measure Hikma Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hikma Pharmaceuticals pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Hikma Return On Equity Analysis

Hikma Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Hikma Pharmaceuticals Return On Equity

    
  0.15  
Most of Hikma Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hikma Pharmaceuticals PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Hikma Pharmaceuticals PLC has a Return On Equity of 0.154. This is 100.64% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The return on equity for all United States stocks is 149.68% lower than that of the firm.

Hikma Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hikma Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hikma Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Hikma Pharmaceuticals by comparing valuation metrics of similar companies.
Hikma Pharmaceuticals is currently under evaluation in return on equity category among related companies.

Hikma Fundamentals

About Hikma Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Hikma Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hikma Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hikma Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company was founded in 1978 and is based in London, the United Kingdom. Hikma Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 8700 people.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Hikma Pharmaceuticals Piotroski F Score and Hikma Pharmaceuticals Altman Z Score analysis.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for Hikma Pink Sheet analysis

When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Please note, there is a significant difference between Hikma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hikma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hikma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.